Beyond usual care: the economic consequences of expanding treatment options in early pregnancy loss

Am J Obstet Gynecol. 2015 Feb;212(2):177.e1-6. doi: 10.1016/j.ajog.2014.08.031. Epub 2014 Aug 28.

Abstract

Objective: The objective of this study was to estimate the economic consequences of expanding options for early pregnancy loss (EPL) treatment beyond expectant management and operating room surgical evacuation (usual care).

Study design: We constructed a decision model using a hypothetical cohort of women undergoing EPL management within a 30 day horizon. Treatment options under the usual care arm include expectant management and surgical uterine evacuation in an operating room (OR). Treatment options under the expanded care arm included all evidence-based safe and effective treatment options for EPL: expectant management, misoprostol treatment, surgical uterine evacuation in an office setting, and surgical uterine evacuation in an OR. Probabilities of entering various treatment pathways were based on previously published observational studies.

Results: The cost per case was US $241.29 lower for women undergoing treatment in the expanded care model as compared with the usual care model (US $1033.29 per case vs US $1274.58 per case, expanded care and usual care, respectively). The model was the most sensitive to the failure rate of the expectant management arm, the cost of the OR surgical procedure, the proportion of women undergoing an OR surgical procedure under usual care, and the additional cost per patient associated with implementing and using the expanded care model.

Conclusion: This study demonstrates that expanding women's treatment options for EPL beyond what is typically available can result in lower direct medical expenditures.

Keywords: decision model; early pregnancy loss treatment; office procedures.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Abortifacient Agents, Nonsteroidal / economics*
  • Abortifacient Agents, Nonsteroidal / therapeutic use
  • Abortion, Spontaneous / economics*
  • Abortion, Spontaneous / therapy
  • Ambulatory Surgical Procedures / economics*
  • Dilatation and Curettage / economics*
  • Dilatation and Curettage / methods
  • Evidence-Based Medicine / economics
  • Female
  • Health Care Costs
  • Humans
  • Misoprostol / economics*
  • Misoprostol / therapeutic use
  • Models, Economic
  • Operating Rooms / economics
  • Pregnancy
  • Pregnancy Trimester, First
  • Watchful Waiting

Substances

  • Abortifacient Agents, Nonsteroidal
  • Misoprostol